SCHEMBL9545044

SCHEMBL9545044

COC(=O)C(C)c1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.60
PTGS2 P35354 1/20 0.60
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HPGD P15428 3/20 0.49
ALOX15 P16050 1/20 0.46
MT-CO2 P00403 1/20 0.46
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
OGG1 O15527 1/20 0.45
CHRNA1 P02708 1/20 0.45
CHRNG P07510 1/20 0.45
ITGA5 P08648 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16364505 1.00 PTGS1 (0.60) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL15811721 0.84 KMT2A (0.61) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL16322386 0.83 PSEN1 (0.49) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL1712790 0.83 KMT2A (0.49) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL1525273 0.83 KMT2A (0.49) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL1525272 0.83 KMT2A (0.49) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL27278587 0.82 APP (0.56) PTGS1PTGS2KMT2ASMN1; SMN2HPGD
SCHEMBL27613551 0.82 TRPM8 (0.48) PTGS1PTGS2KMT2AMEN1SMN1; SMN2
SCHEMBL19030547 0.81 KMT2A (0.48) PTGS1PTGS2KMT2AMEN1NPC1
SCHEMBL30264834 0.81 KMT2A (0.48) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704117-B1 AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS ALCON INC (CH) 2026-01-28 EP disclosed
US-12247028-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2025-03-11 US disclosed
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2024-04-25 US disclosed
US-11884666-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2024-01-30 US disclosed
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2022-08-25 US disclosed
US-11306090-B2 Azabicyclo and diazepine derivatives ALCON INC. (CH) 2022-04-19 US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 US disclosed
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES ALCON INC. (CH) 2021-06-17 US disclosed
CN-111247147-A Azabicyclo and diazepatriene derivatives useful for treating ocular disorders 爱尔康公司 2020-06-05 CN disclosed
US-9771362-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2017-09-26 US disclosed
US-20140187538-A1 LORCASERIN HYDROCHLORIDE DR. REDDY'S LABORATORIES LTD. (IN) 2014-07-03 US disclosed
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-06-05 US disclosed
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-06-05 US disclosed
US-8431596-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-04-30 US disclosed
US-8431596-B2 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-04-30 US disclosed
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed
WO-2009047514-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-16 WO disclosed
US-5260277-A Cell receptor antagonists TANABE SEIYAKU CO., LTD. (JP) 1993-11-09 US disclosed
WO-1993008823-A1 GUANIDINYL AND RELATED CELL ADHESION MODULATION COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 1993-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884666-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885
US-20240132497-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885
US-20210179616-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885
US-20100298339-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PTGS1 2063/4885PTGS2 2708/4885KMT2A 1539/4885
US-20140155594-A1 [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use AXL, TYRO3, FLT3 PTGS1 2063/4885PTGS2 2708/4885KMT2A 1539/4885
US-20140187538-A1 LORCASERIN HYDROCHLORIDE CEL, HTR4, HTR5A PTGS1 4416/4885PTGS2 4597/4885KMT2A 1451/4885
US-20220267328-A1 AZABICYCLO AND DIAZEPINE DERIVATIVES CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885
US-12247028-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885
US-11306090-B2 Azabicyclo and diazepine derivatives CHRM3, CHRM5, CHRNA5 PTGS1 1342/4885PTGS2 1479/4885KMT2A 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.